专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

11. 发明申请

US20090233901A1 VLA-4 INHIBITORY DRUG 失效
标题翻译： VLA-4抑制药物
公开(公告)号：US20090233901A1
公开(公告)日：2009-09-17
申请号：US12097269
申请日：2006-12-13
申请人： Nobuo Machinaga , Shin Iimura , Yoshiyuki Yoneda , Jun Chiba , Fumihito Muro , Hideko Hoh , Atsushi Nakayama
发明人： Nobuo Machinaga , Shin Iimura , Yoshiyuki Yoneda , Jun Chiba , Fumihito Muro , Hideko Hoh , Atsushi Nakayama
IPC分类号： A61K31/403 , A61K31/553 , A61K31/54 , A61K31/5377 , A61K31/415 , C07D409/14 , C07D417/14 , C07D413/14 , C07D403/00 , C07D403/02 , C07D231/56 , C07D403/14 , C07D405/14
CPC分类号： C07D409/12 , C07D401/12 , C07D401/14 , C07D403/12 , C07D403/14 , C07D405/12 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14 , C07D487/08 , C07D491/048 , C07D491/056 , C07D491/08 , C07D495/04
摘要： There is provided a VLA-4 inhibitory drug having good oral absorbability and exhibiting sufficient anti-inflammatory effects when administered orally.A compound represented by the following formula (I): wherein R1 represents a hydrogen atom or a C1-8 alkyl group; R2 represents a hydrogen atom, a halogen atom, a C1-8 alkoxy group, or a benzyloxy group which may be substituted; Q represents a monocyclic or bicyclic nitrogen-containing heterocyclic group which may be substituted, and has a nitrogen atom as the bonding site; Y represents an oxygen atom or CH2; W represents a bicyclic aromatic hydrocarbon ring group which may be substituted, or a bicyclic aromatic heterocyclic group which may be substituted; R3a, R3b and R3c each independently represent a hydrogen atom, a halogen atom, a C1-8 alkoxy group or a C1-8 alkyl group; and A1 represents a nitrogen atom or C—R3d (wherein R3d represents a hydrogen atom, a halogen atom, a C1-8 alkoxy group or a C1-8 alkyl group), or a salt thereof, or a VLA-4 inhibitory drug comprising the compound or the salt as an active ingredient.
摘要翻译：提供口服吸收性良好的VLA-4抑制药物，口服给药时具有足够的抗炎作用。由下式（I）表示的化合物：其中R1表示氢原子或C1-8烷基; R2表示氢原子，卤素原子，C1-8烷氧基或可被取代的苄氧基; Q表示可以被取代的单环或双环含氮杂环基，并且具有氮原子作为键合位点; Y表示氧原子或CH2; W表示可被取代的双环芳香族烃环基或可被取代的双环芳香族杂环基; R3a，R3b和R3c各自独立地表示氢原子，卤素原子，C1-8烷氧基或C1-8烷基; A1表示氮原子或C-R3d（其中R3d表示氢原子，卤原子，C1-8烷氧基或C1-8烷基）或其盐或VLA-4抑制药，其包含化合物或盐作为活性成分。

12. 发明授权

US07179819B2 VLA-4 inhibitor compounds 失效
标题翻译： VLA-4抑制剂化合物
公开(公告)号：US07179819B2
公开(公告)日：2007-02-20
申请号：US10787905
申请日：2004-02-26
申请人： John J. Baldwin , Edward McDonald , Kevin Joseph Moriarty , Christopher Ronald Sarko , Nobuo Machinaga , Atsushi Nakayama , Jun Chiba , Iimura Shin , Yoshiyuki Yoneda
发明人： John J. Baldwin , Edward McDonald , Kevin Joseph Moriarty , Christopher Ronald Sarko , Nobuo Machinaga , Atsushi Nakayama , Jun Chiba , Iimura Shin , Yoshiyuki Yoneda
IPC分类号： C07D277/04 , A61K31/425 , C07D207/12
CPC分类号： C07D207/08 , C07C275/42 , C07C2601/02 , C07D207/09 , C07D207/12 , C07D207/14 , C07D207/16 , C07D207/22 , C07D207/24 , C07D209/12 , C07D211/26 , C07D211/34 , C07D211/38 , C07D213/55 , C07D217/02 , C07D277/04 , C07D277/28 , C07D277/48 , C07D295/13 , C07D295/185 , C07D307/33 , C07D311/20 , C07D401/06 , C07D401/12 , C07D401/14 , C07D403/02 , C07D413/06 , C07D491/04
摘要： Compounds that selectively inhibit the binding of ligands to α4β1 integrin (VLA-4) and methods for their preparation are disclosed. In one embodiment, compounds of the invention are represented by Formula I: As selective inhibitors of VLA-4 mediated cell adhesion, compounds of the present invention are useful in the treatment of conditions associated with such adhesion, including, but not limited to, such conditions as inflammatory and autoimmune responses, diabetes, asthma, psoriasis, inflammatory bowel disease, transplantation rejection, and tumor metastasis. Also disclosed are methods of inhibiting VLA-4 mediated cell adhesion and methods of treating conditions associated with LA-4 mediated cell adhesion.
摘要翻译：公开了选择性抑制配体与α4β1整联蛋白（VLA-4）的结合的化合物及其制备方法。在一个实施方案中，本发明的化合物由式I表示：作为VLA-4介导的细胞粘附的选择性抑制剂，本发明的化合物可用于治疗与这种粘附相关的病症，包括但不限于此作为炎症和自身免疫反应的病症，糖尿病，哮喘，牛皮癣，炎性肠病，移植排斥反应和肿瘤转移。还公开了抑制VLA-4介导的细胞粘附的方法以及治疗与LA-4介导的细胞粘附相关的病症的方法。

13. 发明授权

US09120835B2 Phosphoric acid ester derivatives 有权
标题翻译：磷酸酯衍生物
公开(公告)号：US09120835B2
公开(公告)日：2015-09-01
申请号：US14129596
申请日：2012-06-27
申请人： Nobuo Machinaga , Jun Chiba , Ryuji Hashimoto , Mamoru Otoyo , Ryotaku Inoue
发明人： Nobuo Machinaga , Jun Chiba , Ryuji Hashimoto , Mamoru Otoyo , Ryotaku Inoue
IPC分类号： C07F9/6506 , C07F9/6558 , C07F7/18 , C07F9/572
CPC分类号： C07F9/6506 , C07F7/1804 , C07F9/572 , C07F9/65583
摘要： To provide a novel compound that has S1P lyase inhibitory ability and induces a reduction in the number of lymphocytes, or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition containing the compound or pharmaceutically acceptable salt thereof as an active ingredient. A compound represented by the general formula (I): or a pharmaceutically acceptable salt thereof.
摘要翻译：提供具有S1P裂解酶抑制能力并诱导淋巴细胞数目减少的新型化合物或其药学上可接受的盐，以及含有该化合物或其药学上可接受的盐作为活性成分的药物组合物。由通式（I）表示的化合物或其药学上可接受的盐。

14. 发明申请

US20120157437A1 VLA-4 INHIBITORY DRUG 审中-公开
标题翻译： VLA-4抑制药物
公开(公告)号：US20120157437A1
公开(公告)日：2012-06-21
申请号：US13363990
申请日：2012-02-01
申请人： Nobuo MACHINAGA , Shin Ilmura , Yoshiyuki Yoneda , Jun Chiba , Fumihito Muro , Hideko Hoh , Atsushi Nakayama
发明人： Nobuo MACHINAGA , Shin Ilmura , Yoshiyuki Yoneda , Jun Chiba , Fumihito Muro , Hideko Hoh , Atsushi Nakayama
IPC分类号： A61K31/404 , C07D401/14 , C07D413/14 , A61K31/5377 , C07D417/14 , A61K31/541 , A61K31/553 , A61P29/00 , A61P37/00 , A61P35/04 , A61P11/06 , A61P11/02 , A61P3/10 , A61P19/02 , A61P17/06 , A61P25/00 , A61P1/00 , A61P37/06 , A61P35/02 , A61P37/08 , A61P9/10 , A61P27/02 , A61P1/16 , A61P35/00 , C07D403/14
CPC分类号： C07D409/12 , C07D401/12 , C07D401/14 , C07D403/12 , C07D403/14 , C07D405/12 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14 , C07D487/08 , C07D491/048 , C07D491/056 , C07D491/08 , C07D495/04
摘要： This invention relates to a VLA-4 inhibitory drug, having good oral absorbability and exhibiting sufficient anti-inflammatory effects when administered orally, wherein an active ingredient is represented by formula (I), or a salt thereof: Q represents an optionally-substituted monocyclic or bicyclic nitrogen-containing heterocyclic group having a nitrogen atom as the bonding site; Y represents an oxygen atom or CH2; W represents an optionally-substituted bicyclic aromatic hydrocarbon ring group or an optionally-substituted bicyclic aromatic heterocyclic group; A1 represents a nitrogen atom or C—R3d wherein R3d represents a hydrogen atom, a halogen atom, a C1-8 alkoxy group or a C1-8 alkyl group; R1 represents H or a C1-8 alkyl group; R2 represents H, a halogen, a C1-8 alkoxy group, or an optionally-substituted benzyloxy group; and R3a, R3b and R3c independently represent H, a halogen atom, a C1-8 alkoxy group or a C1-8 alkyl group.
摘要翻译：本发明涉及具有良好口服吸收性且口服给药时具有足够抗炎作用的VLA-4抑制药物，其中活性成分由式（I）表示，或其盐：Q表示任选取代的单环或具有氮原子的双环含氮杂环基作为键合位置; Y表示氧原子或CH2; W表示任选取代的双环芳烃环基或任选取代的双环芳族杂环基; A1表示氮原子或C-R3d，其中R3d表示氢原子，卤素原子，C1-8烷氧基或C1-8烷基; R1表示H或C1-8烷基; R 2表示H，卤素，C 1-8烷氧基或任选取代的苄氧基; R3a，R3b和R3c独立地表示H，卤素原子，C1-8烷氧基或C1-8烷基。

15. 发明申请

US20080050267A1 Au Alloy Bonding Wire 审中-公开
标题翻译： Au合金接合线
公开(公告)号：US20080050267A1
公开(公告)日：2008-02-28
申请号：US11664058
申请日：2005-09-28
申请人： Hiroshi Murai , Jun Chiba , Satoshi Teshima
发明人： Hiroshi Murai , Jun Chiba , Satoshi Teshima
IPC分类号： C22C5/02
CPC分类号： C22C5/02 , B23K35/3013 , H01L24/43 , H01L24/45 , H01L2224/05624 , H01L2224/45015 , H01L2224/45144 , H01L2224/48624 , H01L2224/48639 , H01L2224/85439 , H01L2924/00011 , H01L2924/01105 , H01L2924/01202 , H01L2924/01203 , H01L2924/01205 , H01L2924/01327 , H01L2924/014 , H01L2924/10253 , H01L2924/14 , H01L2924/1576 , H01L2924/181 , H01L2924/19043 , H01L2924/20751 , H01L2924/20752 , H01L2924/01046 , H01L2924/01014 , H01L2924/01063 , H01L2924/01004 , H01L2924/01058 , H01L2924/01064 , H01L2924/01012 , H01L2924/01039 , H01L2924/01057 , H01L2924/01078 , H01L2924/01201 , H01L2924/00014 , H01L2924/0102 , H01L2924/01066 , H01L2924/0103 , H01L2924/0105 , H01L2924/013 , H01L2924/00013 , H01L2924/00 , H01L2924/01028 , H01L2924/01404 , H01L2924/01006
摘要： Provided is a thin Au alloy bonding wire having desired strength, good bondability and stability over time, and improved circularity of a squashed ball and sphericity of a melted ball. The Au alloy bonding wire contains, in an Au alloy matrix containing 0.05 to 2 mass % in total of at least one selected from Pd and Pt of high purity in Au of high purity, as trace elements, 10 to 100 ppm by mass of Mg, 5 to 100 ppm by mass of Ce, and 5 to 100 ppm by mass of each of at least one selected from Be, Y, Gd, La, Eu and Si, the total content of Be, Y, Gd, La, Eu and Si being 5 to 100 ppm by mass, or as trace elements, Mg, Be, and at least one selected from Y, La, Eu and Si, or as trace elements, 10 to 100 ppm by mass of Mg, 5 to 30 ppm by mass of Si, 5 to 30 ppm by mass of Be, and 5 to 30 ppm by mass of at least one selected from Ca, Ce and Sn.
摘要翻译：提供具有期望强度，良好的粘合性和随时间稳定性的薄Au合金接合线，并且改善压扁球的圆形度和熔融球的球形度。 Au合金接合线含有0.05〜2质量％的Au系合金基体，作为微量元素，含有0.05〜2质量％的选自高纯度的Au中的高纯度的Pd和Pt中的至少1种，10〜100质量ppm的Mg ，Ce：5〜100质量ppm，Be，Y，Gd，La，Eu和Si中的至少一种中的至少一种为5〜100质量ppm，Be，Y，Gd，La，Eu的总含量 Si为5〜100质量ppm，作为微量元素，Mg，Be，选自Y，La，Eu，Si中的至少一种，微量元素为10〜100质量ppm，Mg为5〜30 Si为质量ppm，Be为5〜30质量ppm，选自Ca，Ce，Sn中的至少1种为5〜30质量ppm。

16. 发明申请

US20070054909A1 VLA-4 inhibitor compounds 审中-公开
公开(公告)号：US20070054909A1
公开(公告)日：2007-03-08
申请号：US11594432
申请日：2006-11-08
申请人： John Baldwin , Edward McDonald , Kevin Moriarty , Christopher Sarko , Nobuo Machinaga , Atsushi Nakayama , Jun Chiba , Shin Iimura , Yoshiyuki Yoneda
发明人： John Baldwin , Edward McDonald , Kevin Moriarty , Christopher Sarko , Nobuo Machinaga , Atsushi Nakayama , Jun Chiba , Shin Iimura , Yoshiyuki Yoneda
IPC分类号： A61K31/5375 , A61K31/496 , A61K31/4439 , A61K31/426 , A61K31/401 , A61K31/405 , C07D403/02
CPC分类号： C07D207/08 , C07C275/42 , C07C2601/02 , C07D207/09 , C07D207/12 , C07D207/14 , C07D207/16 , C07D207/22 , C07D207/24 , C07D209/12 , C07D211/26 , C07D211/34 , C07D211/38 , C07D213/55 , C07D217/02 , C07D277/04 , C07D277/28 , C07D277/48 , C07D295/13 , C07D295/185 , C07D307/33 , C07D311/20 , C07D401/06 , C07D401/12 , C07D401/14 , C07D403/02 , C07D413/06 , C07D491/04
摘要： Compounds that selectively inhibit the binding of ligands to α4β1 integrin (VLA-4) and methods for their preparation are disclosed. In one embodiment, compounds of the invention are represented by Formula I: As selective inhibitors of VLA-4 mediated cell adhesion, compounds of the present invention are useful in the treatment of conditions associated with such adhesion, including, but not limited to, such conditions as inflammatory and autoimmune responses, diabetes, asthma, psoriasis, inflammatory bowel disease, transplantation rejection, and tumor metastasis. Also disclosed are methods of inhibiting VLA-4 mediated cell adhesion and methods of treating conditions associated with LA-4 mediated cell adhesion.

17. 发明授权

US07157487B2 Vla-4 inhibitors 失效
标题翻译： Vla-4抑制剂
公开(公告)号：US07157487B2
公开(公告)日：2007-01-02
申请号：US10451159
申请日：2001-12-28
申请人： Atsushi Nakayama , Nobuo Machinaga , Yoshiyuki Yoneda , Yuichi Sugimoto , Jun Chiba , Toshiyuki Watanabe , Shin Iimura
发明人： Atsushi Nakayama , Nobuo Machinaga , Yoshiyuki Yoneda , Yuichi Sugimoto , Jun Chiba , Toshiyuki Watanabe , Shin Iimura
IPC分类号： A61K31/405 , C07D209/04
CPC分类号： C07D263/58 , C07C275/42 , C07D209/42 , C07D401/12 , C07D401/14 , C07D403/12 , C07D413/06 , C07D413/12 , C07D413/14 , C07D417/06 , C07D417/12 , C07D471/04 , C07D491/04
摘要： The present invention relates to a compound represented by the following formula (I): (wherein, W represents WA-A1-WB- (in which, WA is substituted or unsubstituted aryl, etc., A1 is —NR1—, single bond, —C(O)—, etc., and WB is substituted or unsubstituted arylene, etc.), R is single bond, —NH—, —OCH2—, alkenylene, etc., X is —C(O)—, —CH2—, etc., and M is, for example, the following formula: (in which, R11, R12 and R13 each independently represents hydrogen, hydroxyl, amino, halogen, etc., R14 is hydrogen or lower alkyl, Y represents —CH2—O—, etc., Z is substituted or unsubstituted arylene, etc., A2 is single bond, etc, and R10 is hydroxyl or lower alkoxy)), or salt thereof; and a medicament containing the same. This compound or salt thereof selectively inhibits binding of cell adhesion molecules to VLA-4 and exhibits high bioavailability so that it is useful as a preventive and/or remedy for inflammatory diseases, autoimmune diseases, metastasis, bronchial asthma, rhinostenosis, diabetes, and the like.
摘要翻译：本发明涉及由下式（I）表示的化合物：（其中，W表示W A，A，B， - （其中，W A是取代或未取代的芳基等，A 1是-NR 1 - 单键，-C （O） - 等，W B是取代或未取代的亚芳基等），R是单键，-NH-，-OCH 2 - ，亚烯基等等，X是-C（O） - ， - CH 2 - 等，M是例如下式：（其中R 11， R 12，R 12和R 13各自独立地表示氢，羟基，氨基，卤素等，R 14是氢或低级烷基，Y表示-CH 2 -O-O-等，Z是取代或未取代的亚芳基等，A 2是单键等，R“ 10是羟基或低级烷氧基））或其盐; 和含有该药物的药物。该化合物或其盐选择性地抑制细胞粘附分子与VLA-4的结合并且表现出高的生物利用度，使得其可用作炎性疾病，自身免疫性疾病，转移，支气管哮喘，鼻窦炎，糖尿病的预防和/或补救。喜欢。

18. 发明授权

US5896250A Head transport mechanism for disc drive apparatus 失效
标题翻译：磁盘驱动装置的磁头传送机构
公开(公告)号：US5896250A
公开(公告)日：1999-04-20
申请号：US971943
申请日：1997-11-17
申请人： Jun Chiba , Takashi Nakai
发明人： Jun Chiba , Takashi Nakai
IPC分类号： G11B5/55 , G11B17/04 , G11B21/02 , G11B21/08
CPC分类号： G11B17/0438 , G11B21/02 , G11B5/5521
摘要： A head transport mechanism for reciprocating a carriage in a radial direction of a disc using a linear motor as a drive source is disclosed. In the head transport mechanism, cylindrical projections are formed on a support plate, threads are cut on the inner surfaces of the projections, and cutouts are formed in the distal ends of bottom yokes. The cutouts are brought into contact with the outer peripheral surfaces of the projections so as to locate the bottom yoke. In addition, protrusions protruding outward from superposed portions of the bottom yokes and top yokes in a longitudinal and/or lateral direction of the bottom yokes are formed in at least one end of each of the bottom yokes so that the top yokes can be assembled with the protrusions pressed when assembling the head transport mechanism.
摘要翻译：公开了一种用于使用线性电动机作为驱动源在盘的径向方向上使托架往复运动的头部运送机构。在头部传送机构中，在支撑板上形成圆柱形突起，在突起的内表面上切割螺纹，并且在底部轭的远端形成切口。切口与突起的外周表面接触，以便定位底部轭。此外，在底轭的纵向和/或横向方向上从底轭和顶轭的重叠部分向外突出的突起形成在每个底轭的至少一端，使得顶轭可以与当组装头部传送机构时，突起被按压。

19. 发明授权

US08129366B2 VLA-4 inhibitory drug 失效
标题翻译： VLA-4抑制药
公开(公告)号：US08129366B2
公开(公告)日：2012-03-06
申请号：US12097269
申请日：2006-12-13
申请人： Nobuo Machinaga , Shin Iimura , Yoshiyuki Yoneda , Jun Chiba , Fumihito Muro , Hideko Hoh , Atsushi Nakayama
发明人： Nobuo Machinaga , Shin Iimura , Yoshiyuki Yoneda , Jun Chiba , Fumihito Muro , Hideko Hoh , Atsushi Nakayama
IPC分类号： A61K31/553 , C07D243/08
CPC分类号： C07D409/12 , C07D401/12 , C07D401/14 , C07D403/12 , C07D403/14 , C07D405/12 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14 , C07D487/08 , C07D491/048 , C07D491/056 , C07D491/08 , C07D495/04
摘要： There is provided a VLA-4 inhibitory drug having good oral absorbability and exhibiting sufficient anti-inflammatory effects when administered orally.A compound represented by the following formula (I): wherein R1 represents a hydrogen atom or a C1-8 alkyl group; R2 represents a hydrogen atom, a halogen atom, a C1-8 alkoxy group, or a benzyloxy group which may be substituted; Q represents a monocyclic or bicyclic nitrogen-containing heterocyclic group which may be substituted, and has a nitrogen atom as the bonding site; Y represents an oxygen atom or CH2; W represents a bicyclic aromatic hydrocarbon ring group which may be substituted, or a bicyclic aromatic heterocyclic group which may be substituted; R3a, R3b and R3c each independently represent a hydrogen atom, a halogen atom, a C1-8 alkoxy group or a C1-8 alkyl group; and A1 represents a nitrogen atom or C—R3d (wherein R3d represents a hydrogen atom, a halogen atom, a C1-8 alkoxy group or a C1-8 alkyl group), or a salt thereof, or a VLA-4 inhibitory drug comprising the compound or the salt as an active ingredient.
摘要翻译：提供口服吸收性良好的VLA-4抑制药物，口服给药时具有足够的抗炎作用。由下式（I）表示的化合物：其中R1表示氢原子或C1-8烷基; R2表示氢原子，卤素原子，C1-8烷氧基或可被取代的苄氧基; Q表示可以被取代的单环或双环含氮杂环基，并且具有氮原子作为键合位点; Y表示氧原子或CH2; W表示可被取代的双环芳香族烃环基或可被取代的双环芳香族杂环基; R3a，R3b和R3c各自独立地表示氢原子，卤素原子，C1-8烷氧基或C1-8烷基; A1表示氮原子或C-R3d（其中R3d表示氢原子，卤原子，C1-8烷氧基或C1-8烷基）或其盐或VLA-4抑制药，其包含化合物或盐作为活性成分。

20. 发明申请

US20090324581A1 HETEROARYLAMIDE LOWER CARBOXYLIC ACID DERIVATIVE 审中-公开
标题翻译：异丁酰胺低级羧酸衍生物
公开(公告)号：US20090324581A1
公开(公告)日：2009-12-31
申请号：US12299483
申请日：2007-05-09
申请人： Nobuo Machinaga , Toshiharu Yoshino , Jun Chiba , Jun Watanabe , Takashi Suzuki , Youichi Kimura
发明人： Nobuo Machinaga , Toshiharu Yoshino , Jun Chiba , Jun Watanabe , Takashi Suzuki , Youichi Kimura
IPC分类号： A61K39/395 , C07D409/12 , A61K31/405 , A61K31/538 , C07D413/12 , A61K31/4709 , A61K31/397 , C07D409/14
CPC分类号： C07D409/12 , A61K31/404 , A61K31/4155 , A61K31/4709 , A61K31/538 , A61K45/06 , C07D209/08 , C07D401/06 , C07D403/12 , C07D409/06 , C07D409/14 , C07D413/12 , C07D417/12
摘要： To provide a novel compound which has S1P receptor agonistic activity, exhibits excellent immunosuppressing effect, gives less adverse side effects, and can be orally administered.The invention provides a compound represented by general formula (I) (wherein A is a single bond, —O—, or —CH2—; R1 represents a hydrogen atom or a C1-C6 alkyl group, and V represents any one group selected from among the following groups (1) to (3): (1) -G1-, (2) -G2-N(R2)-G3-, and (3) a group represented by formula 2, wherein each of Z1 and Z2 represents a hydrogen atom or a C1-C6 alkyl group, Z3 represents a hydrogen or the like, Q represents —CH2—O— or the like, and Y represents a group represented by formula 3, a salt thereof, or a solvate thereof.
摘要翻译：为了提供具有S1P受体激动活性的新化合物，显示出优异的免疫抑制作用，给予较少的副作用，并且可以口服给药。本发明提供由通式（I）表示的化合物（其中A是单键，-O-或-CH 2 - ; R 1表示氢原子或C 1 -C 6烷基，V表示选自在以下组（1）〜（3）中：（1）-G1，（2）-G2-N（R2）-G3-，（3）由式2表示的基团，其中Z1和Z2 表示氢原子或C1-C6烷基，Z3表示氢等，Q表示-CH2-O-等，Y表示由式3表示的基团，其盐或其溶剂合物。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式